Publications

WHO-cancer-medicines-rebrand

The WHO Technical Report on the Pricing of Cancer Medicines: Missing a central role for HTA and value assessment

1 April 2019

The WHO Technical Report: Pricing of cancer medicines and its impacts (“the Report”) was published in order to address requests made in a resolution adopted by…

Value, Access, and Incentives for Innovation - Policy Perspectives on Alternative Models for Pharmaceutical Rebates

Value, Access, and Incentives for Innovation: Policy Perspectives on Alternative Models for Pharmaceutical Rebates

1 March 2019

OHE Research Paper 19/02: The combination of rising drug costs in the US and increasing financial stress for individual patients has triggered intense national concern. One…

Front Cover (V2)

Exploring Variations in the Opportunity Cost Cost-effectiveness Threshold by Clinical Area: Results from a Feasibility Study in England

1 March 2019

Estimating a cost-effectiveness threshold reflecting the opportunity cost of adopting a new technology in a health system is not easy. This OHE research paper provides empirical…

Cracks through the ice on a melting glacier in Alaska

How Should We Measure Quality of Life Impact in Rare Disease? Recent Learnings in Spinal Muscular Atrophy

1 March 2019

The measurement of quality of life in the context of spinal muscular atrophy (SMA) is challenging. This is because the disease is experienced by children and is rare, which makes data collection difficult. This Briefing reports on a symposium that outlined some lessons that can be learnt from the SMA context that might be more widely applicable.

future-global-health-procurement-rebrand

The Future of Global Health Procurement: Issues around Pricing Transparency

1 March 2019

This OHE Research Paper focuses on the role that price transparency may play in the efficient and effective procurement of medicines by Middle and Low Income…

Early Experience with Health Technology Assessment of Gene Therapies in the United States

Early Experience with Health Technology Assessment of Gene Therapies in the United States: Pricing and Paying for Cures

1 February 2019

Gene therapies, which can provide cures for diseases, are a new area of research for ICER. Some are within two to three years of becoming available…

Making Outcome-Based Payment a Reality in the NHS + corrigendum

Making Outcome-Based Payment a Reality in the NHS

2 January 2019

This report explores the feasibility of introducing one type of flexible payment mechanism – outcome-based payment (OBP) – for cancer medicines into the NHS in England. OBP could help to accelerate patient access to some new medicines and ensure close monitoring of real-world patient benefit.

2018 Annual Lecture

Can a Strong Economic Case Be Made for Investing in the NHS?

1 January 2019

Debate about funding has highlighted the difficulty of persuading sceptics that the NHS is a good use of public finance. There is a widely held view…

Public preferences for health gains & cures

Public Preferences for Health Gains and Cures: A Discrete Choice Experiment

1 January 2019

Whether or not society values curative therapies more highly (or less highly) than the sum of the iterative improvements that might come from conventional therapy has…